Krystal Biotech (KRYS) Convertible Debt (2016)

Krystal Biotech's (KRYS) quarterly Convertible Debt came in at $1.1 million in Q4 2016.

Krystal Biotech (KRYS) Convertible Debt (2016) Analysis & Trends

Krystal Biotech has disclosed Convertible Debt across 1 years of filings, most recently posting $1.1 million for Q4 2016.

Convertible Debt for Q4 2016 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $1.1 million (changed N/A YoY), and the FY2016 annual result was $1.1 million, changed N/A from the prior year.
Convertible Debt came in at $1.1 million for Q4 2016 at Krystal Biotech.
In the past five years, Convertible Debt ranged from a high of $1.1 million in Q4 2016 to a low of $1.1 million in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Krystal Biotech	10.23 Bn	9.41 Bn	110.03 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2016	1.15 Mn